Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 3/20 | 0.61 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | KDM1A | O60341 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254400 | 0.86 | ROCK2 (0.62) | ROCK2ROCK1MAOBSRC | |
| SCHEMBL12190845 | 0.82 | HPGD (0.64) | SCN2ASCN10AROCK2AURKA | |
| SCHEMBL12191062 | 0.81 | HDAC1 (0.67) | SCN2ASCN10AHDAC1KDM1ASMN1; SMN2 | |
| SCHEMBL12190997 | 0.81 | RAB9A (0.51) | SCN2ASCN10AROCK2ROCK1HDAC1 | |
| SCHEMBL12190882 | 0.80 | SCN2A (0.62) | SCN2ASCN10AHDAC1KDM1AMAOB | |
| SCHEMBL14082551 | 0.80 | ROCK2 (0.59) | ROCK2ROCK1AURKASRC | |
| SCHEMBL12190893 | 0.80 | HDAC1 (0.78) | SCN2ASCN10AHDAC1KDM1AMAOB | |
| SCHEMBL12191068 | 0.78 | L3MBTL1 (0.64) | SCN2ASCN10AROCK2ROCK1HDAC1 | |
| SCHEMBL13876853 | 0.78 | SCN2A (0.53) | SCN2ASCN10AHDAC1KDM1AAURKA | |
| SCHEMBL254175 | 0.77 | SRC (0.69) | ROCK2ROCK1HDAC1SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030336-B2 | Nicotinamide-based kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-10-04 | — | — | US | disclosed |
| US-8030336-B2 | Nicotinamide-based kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-10-04 | — | — | US | disclosed |
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | CYTOPIA PTY LTD (AU) | 2007-03-15 | — | — | US | disclosed |
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | CYTOPIA PTY LTD (AU) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | NADK, NAMPT, PDXK | SCN2A 1134/4885SCN10A 1066/4885ROCK2 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.